Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015', provides an overview of the Leishmaniasis (Kala-Azar)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Leishmaniasis (Kala-Azar) Overview 10
Therapeutics Development 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Leishmaniasis (Kala-Azar) - Products under Development by Companies 19
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 20
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 21
Advinus Therapeutics Ltd. 21
Anacor Pharmaceuticals, Inc. 22
BioLingus AG 23
Dafra Pharma International Ltd. 24
iCo Therapeutics Inc. 25
Merck KGaA 26
Mologen AG 27
Nanomerics Ltd 28
Sanofi 29
Takeda Pharmaceutical Company Limited 30
Zydus Cadila Healthcare Limited 31
Leishmaniasis (Kala-Azar) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
18-MC - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
amphotericin b - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
amphotericin B - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
amphotericin B - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
amphotericin b NanoDisk - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AS-605240 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CDRI-99/288 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
corifungin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
fexinidazole - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Indotecan hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
interferon gamma - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KVH-14 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
leishmaniasis vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
leishmaniasis vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
leishmaniasis vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MGN-1331 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NPC-1161B - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Oleylphosphocholine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pegylated amphotericin B - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Polysaccharide for Oncology, Infectious Disease and Allergy - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
S-010269 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule for Leishmaniasis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecule for Leishmaniasis - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule for Visceral Leishmaniasis - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules for Infectious Disease and Oncology - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules for Infectious Diseases - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Infectious Diseases - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules for Leishmaniasis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Leishmaniasis - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Leishmaniasis - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for Protozoal Infections - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Visceral Leishmaniasis - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for Visceral Leishmaniasis - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small molecules to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Synthetic Peptides for Infectious Disease - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
visceral leishmaniasis vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
VL-2098 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 88
Leishmaniasis (Kala-Azar) - Dormant Projects 92
Leishmaniasis (Kala-Azar) - Discontinued Products 93
Leishmaniasis (Kala-Azar) - Product Development Milestones 94
Featured News & Press Releases 94
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 94
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 94
Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 94
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 95
Dec 17, 2012: PATH's Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 96
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 98
Disclaimer 99

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2015 11
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Investigation by Universities/Institutes, H2 2015 20
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H2 2015 21
Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 22
Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2015 23
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H2 2015 24
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2015 25
Leishmaniasis (Kala-Azar) - Pipeline by Merck KGaA, H2 2015 26
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H2 2015 27
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2015 28
Leishmaniasis (Kala-Azar) - Pipeline by Sanofi, H2 2015 29
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 30
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 31
Assessment by Monotherapy Products, H2 2015 32
Number of Products by Stage and Target, H2 2015 34
Number of Products by Stage and Mechanism of Action, H2 2015 36
Number of Products by Stage and Route of Administration, H2 2015 38
Number of Products by Stage and Molecule Type, H2 2015 40
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H2 2015 88
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2015 92
Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2015 93